CXCL9 and hepatocellular carcinoma: Despite the limited size of our HCC cohort, TIPC successfully identified key spatial interactions, thereby validating the anticipated importance of the CXCL9-CXCR3 axis in HCC patient responses to the combined treatment of Y90-radioembolization and nivolumab.